Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery

Postmortem Analysis in a Clinical Trial of AAV2-NGF Gene Therapy for Alzheimer’s Disease Identifies a Need for Improved Vector Delivery

(2020) Michael J. Castle et al.   HUMAN GENE THERAPY

Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood–brain barrier disruption: where are we now, and where we are going

(2020) Randy S. D’Amico et al.   JOURNAL OF NEURO-ONCOLOGY

Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain

(2020) William M. Pardridge   Frontiers in Aging Neuroscience

Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys

(2020) Mihalis S. Kariolis et al.   Science Translational Medicine

The Isolated Brain Microvessel: A Versatile Experimental Model of the Blood-Brain Barrier

(2020) William M. Pardridge   Frontiers in Physiology

The coevolution of atomic resolution and whole-brain imaging for tau neurofibrillary tangles

(2020) Raeann M. Dalton et al.   ACS Chemical Neuroscience

Anti-Amyloid-β Protein agents for the treatment of Alzheimer’s Disease: An update on emerging drugs

(2020) Madia Lozupone et al.   EXPERT OPINION ON EMERGING DRUGS

Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model

(2020) Shoutang Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

(2020) Martin Tolar et al.   Alzheimers Research & Therapy

Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia

(2020) Suzanne Craft et al.   JAMA Neurology

A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders

(2020) Sagrario Manzano et al.   Frontiers in Neurology

Abundance of P‐Glycoprotein and Other Drug Transporters at the Human Blood‐Brain Barrier in Alzheimer’s Disease: A Quantitative Targeted Proteomic Study

(2020) Flavia Storelli et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer’s disease

(2020) Tobias Gustavsson et al.   Translational Neurodegeneration

Acute and Chronic Dosing of a High-Affinity Rat/Mouse Chimeric Transferrin Receptor Antibody in Mice

(2020) Demi M. Castellanos et al.   Pharmaceutics

Characterization of tau binding by gosuranemab

(2020) Richelle Sopko et al.   NEUROBIOLOGY OF DISEASE

Structural characterization of monoclonal antibodies targeting C-terminal Ser404 region of phosphorylated tau protein

(2019) Jessica E. Chukwu et al.   mAbs

A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment

(2019) Brati Das et al.   CNS DRUGS

Alzheimer’s disease: future drug development and the blood-brain barrier

(2019) William M. Pardridge   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice

(2019) Jiahong Sun et al.   MOLECULAR PHARMACEUTICS

Ultrasound-mediated blood-brain barrier opening enhances delivery of therapeutically relevant formats of a tau-specific antibody

(2019) Phillip W. Janowicz et al.   Scientific Reports

The neuropathological diagnosis of Alzheimer’s disease

(2019) Michael A. DeTure et al.   Molecular Neurodegeneration

IVIVC Assessment of Two Mouse Brain Endothelial Cell Models for Drug Screening

(2019) Ina Puscas et al.   Pharmaceutics

The amyloid-β degradation intermediate Aβ34 is pericyte-associated and reduced in brain capillaries of patients with Alzheimer’s disease

(2019) Tunahan Kirabali et al.   Acta Neuropathologica Communications

Aβ 1–42 oligomer induces alteration of tight junction scaffold proteins via RAGE-mediated autophagy in bEnd.3 cells

(2018) Yuanjin Chan et al.   EXPERIMENTAL CELL RESEARCH

Antibody pharmacokinetics in rat brain determined using microdialysis

(2018) Hsueh-Yuan Chang et al.   mAbs

Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial

(2018) Roberto Giugliani et al.   Orphanet Journal of Rare Diseases

Adeno-Associated Viral Vector (Serotype 2)–Nerve Growth Factor for Patients With Alzheimer Disease

(2018) Michael S. Rafii et al.   JAMA Neurology

Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β

(2018) Bernd Bohrmann et al.   JOURNAL OF ALZHEIMERS DISEASE

TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading

(2018) Heidi Martini-Stoica et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor

(2018) William M. Pardridge et al.   MOLECULAR PHARMACEUTICS

A Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer’s Disease

(2018) Rudy Chang et al.   MOLECULAR PHARMACEUTICS

New insights into the role of TREM2 in Alzheimer’s disease

(2018) Maud Gratuze et al.   Molecular Neurodegeneration

Kinetics and MR-Based Monitoring of AAV9 Vector Delivery into Cerebrospinal Fluid of Nonhuman Primates

(2018) Kousaku Ohno et al.   Molecular Therapy-Methods & Clinical Development

Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery

(2017) Michelle E. Pizzo et al.   JOURNAL OF PHYSIOLOGY-LONDON

Blood–Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer’s Disease

(2017) Rudy Chang et al.   MOLECULAR PHARMACEUTICS

Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates

(2017) Clemens Braun et al.   MOLECULAR PHARMACEUTICS

Blood-brain barrier disruption induced by diagnostic ultrasound combined with microbubbles in mice

(2017) Bingxia Zhao et al.   Oncotarget

Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor

(2017) Greta Hultqvist et al.   Theranostics

Visualization of drug translocation in the nasal cavity and pharmacokinetic analysis on nasal drug absorption using positron emission tomography in the rat

(2016) Tomotaka Shingaki et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

CSF, blood-brain barrier, and brain drug delivery

(2016) William M. Pardridge   Expert Opinion on Drug Delivery

Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease

(2016) Syed Faraz Kazim et al.   Molecular Neurodegeneration

Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey

(2016) Ruben J. Boado et al.   MOLECULAR PHARMACEUTICS

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Neuronal uptake of serum albumin is associated with neuron damage during the development of epilepsy

(2016) Zanhua Liu et al.   Experimental and Therapeutic Medicine

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

(2016) Veronika Logovinsky et al.   Alzheimers Research & Therapy

Blood–brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery

(2015) William M Pardridge   EXPERT OPINION ON THERAPEUTIC TARGETS

Immunohistochemical analysis of transporters related to clearance of amyloid-β peptides through blood–cerebrospinal fluid barrier in human brain

(2015) Koichi Matsumoto et al.   HISTOCHEMISTRY AND CELL BIOLOGY

Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial

(2015) J. Butchart et al.   NEUROLOGY

Central delivery of iodine-125–labeled cetuximab, etanercept and anakinra after perispinal injection in rats: possible implications for treating Alzheimer’s disease

(2015) Megan E. Roerink et al.   Alzheimers Research & Therapy

Comparative Physiology of Mice and Rats: Radiometric Measurement of Vascular Parameters in Rodent Tissues

(2014) C. Andrew Boswell et al.   MOLECULAR PHARMACEUTICS

Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle

(2014) Jens Niewoehner et al.   NEURON

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates

(2014) Y. J. Yu et al.   Science Translational Medicine

Atherosclerosis and Alzheimer - diseases with a common cause? Inflammation, oxysterols, vasculature

(2014) Richard Lathe et al.   BMC Geriatrics

Disaggregation of Amyloid Plaque in Brain of Alzheimer’s Disease Transgenic Mice with Daily Subcutaneous Administration of a Tetravalent Bispecific Antibody That Targets the Transferrin Receptor and the Abeta Amyloid Peptide

(2013) Rachita K. Sumbria et al.   MOLECULAR PHARMACEUTICS

Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier

(2013) J. A. Couch et al.   Science Translational Medicine

IgG-Enzyme Fusion Protein: Pharmacokinetics and Anti-Drug Antibody Response in Rhesus Monkeys

(2012) Ruben J. Boado et al.   BIOCONJUGATE CHEMISTRY

Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice

(2012) Frédérique Bard et al.   EXPERIMENTAL NEUROLOGY

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

(2012) Peter T. Nelson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

(2012) Reisa Sperling et al.   LANCET NEUROLOGY

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)

(2011) Paul S. Aisen et al.   Archives of Medical Science

Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse

(2011) Qing-Hui Zhou et al.   BRAIN RESEARCH

A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-  Production in Vivo

(2011) J. K. Atwal et al.   Science Translational Medicine

Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein

(2010) Ruben J. Boado et al.   JOURNAL OF BIOTECHNOLOGY

Drug Targeting of Erythropoietin Across the Primate Blood-Brain Barrier with an IgG Molecular Trojan Horse

(2010) R. J. Boado et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Histological studies of the effects of chronic implantation of ceramic-based microelectrode arrays and microdialysis probes in rat prefrontal cortex

(2009) Erin R. Hascup et al.   BRAIN RESEARCH

Blood–brain barrier permeability in Alzheimer's disease: a case–control MRI study

(2009) John M. Starr et al.   PSYCHIATRY RESEARCH-NEUROIMAGING

Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke

(2009) Hannelore Ehrenreich et al.   STROKE

Erythropoietins: A common mechanism of action

(2008) Steve Elliott et al.   EXPERIMENTAL HEMATOLOGY

The distribution of D2/D3 receptor binding in the adolescent rhesus monkey using small animal PET imaging

(2008) B CHRISTIAN et al.   NEUROIMAGE